Fundamentals · DHR
Valuation Summary for DHR
AI-generated plain-English read of valuation summary for DHR. Updated daily.
Rich multiples, stable
moderateRich multiples (36.6x) with stable trajectory: an expensive hold, but no immediate unwind signal.
What will probably happen
- Multiples are stable: no near-term catalyst for a valuation re-rating from the multiple direction alone.
What to do
- If you HOLD this stock
- Valuation doesn't give a strong signal for or against adding. Hold and monitor earnings delivery against the current multiple.
- If you're EVALUATING this stock
- Expensive entry. If you must own it, wait for a 10–15% multiple compression or a significant earnings beat that 'grows into' the valuation.
- If you trade OPTIONS
- Sell covered calls to reduce effective cost basis while waiting for multiple normalisation. Long puts make sense if you expect a near-term earnings miss to catalyse compression.
9 quarters / 3 populated multiples: directionally informative; use more data for full conviction.
Technical details
Technical analysis
- P/E (trailing)
- 36.6x
- P/E (forward)
- --
- EV/EBITDA
- --
- P/Sales
- 5.4x
- P/Book
- 2.5x
- EV/Revenue
- --
- FCF yield
- --
- Earnings yield
- --
- Dividend yield
- --
- Absolute valuation
- Richly Valued
- Sector comparison
- Unknown Vs Sector
- Multiple trajectory
- Stable
- Income profile
- Growth Profile
- History (quarters)
- 9
- Sector context
- Life Sciences Tools & Services
Key levels
| Level | Value |
|---|---|
| pe ratio | 36.553 |
| ps ratio | 5.442 |
| pb ratio | 2.546 |
| current price | 232.16 |
| prior year pe | 39.247 |
| n quarters | 9 |
Caveats
- Multiples should be read alongside growth and quality metrics: a low P/E on declining earnings isn't cheap, it's a value trap warning.
- Sector context wasn't provided; absolute multiples may mislead without industry comparison.